TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27206218

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus topotecan (1.25 mg/m days 1-5 every 3 weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus paclitaxel (80 mg/m weekly)
Number of subjects: 50
Study: 25211297

Group type: EXPERIMENTAL
Intervention: Severe burn injury
Number of subjects: 97
Study: 22882932

Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation (transcutaneous electrical nerve stimulation, mid-frequency electrotherapy, Tuina therapy, and occupational therapy)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Home-based electrical nerve stimulation and occupational therapy (Control)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation
Number of subjects: 43
Study: 19559446

Group type: EXPERIMENTAL
Intervention: Daytime nap (40 minutes)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Wake condition
Number of subjects: 63
Study: 18622588

Group type: EXPERIMENTAL
Intervention: Computer-aided guidance for discectomy and corpectomy (Trial Group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No computer navigation (Control Group)
Number of subjects: 26
Study: 16459945

Group type: EXPERIMENTAL
Intervention: Usual medical care plus compliance therapy (4-6 sessions, 60 minutes each)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual medical care (n = 20)
Number of subjects: 40
Study: 12856387

Group type: EXPERIMENTAL
Intervention: E5564 (350 micrograms)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: E5564 (1000 micrograms)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: E5564 (2000 micrograms)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: E5564 (3500 micrograms)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: E5564 (all doses)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: E5564 (2000 and 3500 micrograms)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: E5564 (up to 3500 micrograms)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 10391557

Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT) of 12-25 Gy
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT) of 25 Gy
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT) of 12-20 Gy
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT)
Number of subjects: 121
Study: 8897331

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 40
Study: 1515884

Group type: EXPERIMENTAL
Intervention: 44 mg/kg of VP‐16 + 103 mg/kg CY followed by 12 Gy TBI (autologous marrow recipients)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 36 mg/kg of VP‐16 + 67 mg/kg CY followed by 12 Gy TBI (allogeneic marrow recipients)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combination of etoposide and cyclophosphamide with TBI
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Dose limiting toxicities
Number of subjects: 37
Study: 6828969

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Combination of cephalothin-tobramycin
Number of subjects: 100
Study: 30318931

Group type: EXPERIMENTAL
Intervention: Automatic prompting method
Number of subjects: 16

Group type: COMPARATOR
Intervention: User-controlled method
Number of subjects: 16
Study: 29352304

Group type: EXPERIMENTAL
Intervention: Daily text messages
Number of subjects: 638

Group type: COMPARATOR
Intervention: Control group (no text messages)
Number of subjects: 638
Study: 26434564

Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system (RAS) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25187903

Group type: EXPERIMENTAL
Intervention: Endosseous implants with straight emergence profile, ZirTi surface, 3.3 to 5 mm diameter, and 8.5 to 13 mm length
Number of subjects: 252
Study: 21812893

Group type: EXPERIMENTAL
Intervention: Rosiglitazone/Metformin (Rosi/Met, 4/1000 mg)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 19683303

Group type: EXPERIMENTAL
Intervention: 60 shocks per minute
Number of subjects: 163

Group type: COMPARATOR
Intervention: 120 shocks per minute
Number of subjects: 163
Study: 17998769

Group type: EXPERIMENTAL
Intervention: Cilnidipine (10 mg)
Number of subjects: 23
Study: 15277960

Group type: EXPERIMENTAL
Intervention: Alternating electrical stimulation of the extensor and flexor muscles of the hand (group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the extensors only (group B)
Number of subjects: 30
Study: 11990406

Group type: EXPERIMENTAL
Intervention: Buried catheter technique (B group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard catheter technique (NB group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard catheter technique (NS group)
Number of subjects: 60
Study: 9824883

Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 46
Study: 7808829

Group type: EXPERIMENTAL
Intervention: Whey-predominant formula (Similac Special Care, whey:casein ratio 60:40)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Casein-predominant formula (whey:casein ratio 18:82)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both formulas (whey-predominant and casein-predominant)
Number of subjects: 20
Study: 2744943

Group type: EXPERIMENTAL
Intervention: Limbus-based conjunctival flap
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fornix-based conjunctival flap
Number of subjects: 0
Study: 4152716

Group type: EXPERIMENTAL
Intervention: Ordinary Noveril
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Time released Noveril
Number of subjects: 20
Study: 31617830

Group type: EXPERIMENTAL
Intervention: Survivorship planning consultation (experimental arm)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Time-attention control - wellness rehabilitation intervention (control arm)
Number of subjects: 199
Study: 29311072

Group type: EXPERIMENTAL
Intervention: Cefiderocol 100 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cefiderocol 250 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cefiderocol 500 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cefiderocol 1000 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cefiderocol 2000 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cefiderocol 1000 mg q8h
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cefiderocol 2000 mg q8h
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 28845435

Group type: EXPERIMENTAL
Intervention: Sintered nanohydroxyapatite (NHA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Anorganic bovine bone (ABB)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: NHA
Number of subjects: 28

Group type: COMPARATOR
Intervention: ABB
Number of subjects: 28
Study: 25393772

Group type: COMPARATOR
Intervention: Fresh red blood cell transfusions (<14 days)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Older stored red blood cell transfusions (>21 days)
Number of subjects: 43
Study: 23293218

Group type: EXPERIMENTAL
Intervention: IMSI (high-magnification intracytoplasmic morphologically selected sperm injection)
Number of subjects: 350

Group type: COMPARATOR
Intervention: ICSI (conventional intracytoplasmic sperm injection)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: IMSI
Number of subjects: 350

Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 350
Study: 21552177

Group type: EXPERIMENTAL
Intervention: Cholesterol-soaked unworn lenses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Worn PureVision lenses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Worn Acuvue Oasys lenses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cholesterol
Number of subjects: 0
Study: 18710745

Group type: EXPERIMENTAL
Intervention: 1996 trials
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 2004 trials
Number of subjects: 152
Study: 15970791

Group type: EXPERIMENTAL
Intervention: Val/Val genotype
Number of subjects: 1271

Group type: COMPARATOR
Intervention: Ile/Ile genotype
Number of subjects: 1271
Study: 12488964

Group type: EXPERIMENTAL
Intervention: Structured group treatment and teaching programmes for Type I diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured group treatment and teaching programmes for non-insulin dependent Type II diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured group treatment and teaching programmes for hypertension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phased approach defining sequential stages of a continuum of increasing evidence
Number of subjects: 0
Study: 10512131

Group type: EXPERIMENTAL
Intervention: IL-2 alone at 6 x 10(6) Cetus units/m2 3 days weekly
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: IL-2 plus beta-IFN at 5 x 10(6) Cetus units/m2 plus beta-IFN at 6 x 10(6) units/m2, both given 3 days weekly
Number of subjects: 76

Group type: COMPARATOR
Intervention: IL-2 (both groups combined)
Number of subjects: 76
Study: 7491550

Group type: EXPERIMENTAL
Intervention: Fast reduction group (cigarettes with a tar yield of about half their usual brand)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Slow reduction group (reduced to the same level in steps over several months)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Control group (continued smoking cigarettes with a tar yield 10% lower than their usual brand)
Number of subjects: 434
Study: 2022713

Group type: EXPERIMENTAL
Intervention: Daily metGH (0.043 mg/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Three times per week metGH (0.1 mg/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All subjects (combined data)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Daily metGH
Number of subjects: 20

Group type: COMPARATOR
Intervention: Three times per week metGH
Number of subjects: 20
Study: 7075659

Group type: EXPERIMENTAL
Intervention: Indalpine (a selective 5‐HT uptake inhibitor) administered for 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30456814

Group type: EXPERIMENTAL
Intervention: Internet-based personalized feedback, psychoeducation tailored to personal symptom profile, information about available mental health services.
Number of subjects: 1374

Group type: COMPARATOR
Intervention: Control condition (CC)
Number of subjects: 1374
Study: 28328802

Group type: EXPERIMENTAL
Intervention: Neutral macroporous resin hemoperfusion (experiment 1 group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Neutral macroporous resin hemoperfusion (experiment 2 group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 25297946

Group type: EXPERIMENTAL
Intervention: Exercise in polluted air
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ambient air exposure
Number of subjects: 25
Study: 23830290

Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIIE)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Moderate-intensity continuous exercise (MICE)
Number of subjects: 19
Study: 21925203

Group type: EXPERIMENTAL
Intervention: Brief cardiovascular prevention program executed by a health advisor
Number of subjects: 1275
Study: 19016317

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 32
Study: 17570880

Group type: EXPERIMENTAL
Intervention: Individualized intervention (nurse care manager counseling, problem identification, care planning)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Basic intervention (comprehensive evaluation of diabetes)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Individualized intervention with more than 2 contacts with the study nurse
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Individualized intervention with less than 2 contacts with the study nurse
Number of subjects: 197
Study: 15456080

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b (1.5 microg/kg weekly) plus ribavirin (1000-1200mg per day)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b (1.5 microg/kg weekly) plus ribavirin (1000-1200mg per day) plus amantadine (200 mg per day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Peginterferon alpha-2b plus ribavirin
Number of subjects: 63
Study: 11521804

Group type: EXPERIMENTAL
Intervention: BEMP (bleomycin, vindesine, mitomycin-C, and cisplatin)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Cisplatin (P)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: BEMP
Number of subjects: 201
Study: 9921605

Group type: EXPERIMENTAL
Intervention: Eliprodil (a non‐competitive NMDA receptor antagonist)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 452
Study: 7646310

Group type: EXPERIMENTAL
Intervention: ramipril 5 mg/day (N = 37)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: ramipril 1.25 mg/day (N = 38)
Number of subjects: 115

Group type: COMPARATOR
Intervention: placebo (N = 40)
Number of subjects: 115
Study: 2656362

Group type: EXPERIMENTAL
Intervention: Diuresis
Number of subjects: 19

Group type: COMPARATOR
Intervention: Therapeutic paracentesis
Number of subjects: 19
Study: 5067672

Group type: EXPERIMENTAL
Intervention: Horlicks (hot, bedtime, milk-cereal drink)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Inert capsule (control)
Number of subjects: 18
Study: 30916589

Group type: EXPERIMENTAL
Intervention: PELD combined with postoperative three-dimensional traction
Number of subjects: 180

Group type: COMPARATOR
Intervention: Traditional surgery
Number of subjects: 180

Group type: COMPARATOR
Intervention: PELD
Number of subjects: 180
Study: 28764999

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25226826

Group type: EXPERIMENTAL
Intervention: Echium oil (10 g daily providing 1.2 g of SDA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: HOSO (high oleic acid sunflower oil)
Number of subjects: 36
Study: 23055142

Group type: EXPERIMENTAL
Intervention: Mirror image pointing with right arm to left shoulder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blindfolded pointing
Number of subjects: 0
Study: 21646672

Group type: EXPERIMENTAL
Intervention: Hospital-specific factors affecting blood pressure treatment
Number of subjects: 788
Study: 19199498

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium infusion
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Low-dose magnesium infusion
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: High-dose magnesium infusion
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 108
Study: 16762750

Group type: EXPERIMENTAL
Intervention: Preserved LVEF (≥45%)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Reduced LVEF (<45%)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Sinus rhythm with normal LV filling pattern
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Atrial arrhythmias
Number of subjects: 141
Study: 15544588

Group type: EXPERIMENTAL
Intervention: Loratadine 5 mg/day (2.5 mg/day for children ≤24 months of age)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 412
Study: 11021338

Group type: EXPERIMENTAL
Intervention: Cold pressor test (pain induced)
Number of subjects: 41
Study: 9315059

Group type: EXPERIMENTAL
Intervention: Fleet enemas
Number of subjects: 102

Group type: COMPARATOR
Intervention: Picolax
Number of subjects: 102
Study: 8333747

Group type: EXPERIMENTAL
Intervention: Ubenimex
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study: 3365283

Group type: EXPERIMENTAL
Intervention: Indalpine (50 mg/d for initial treatment, 150 mg/d for maintenance)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Indalpine (50 mg/d and 150 mg/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Alcohol (1 g/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31277077

Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nasal Continuous Positive Airway Pressure (NCPAP)
Number of subjects: 30
Study: 31189238

Group type: EXPERIMENTAL
Intervention: Conventional treatment combined with TCM syndrome differentiation
Number of subjects: 160

Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 160
Study: 29180210

Group type: EXPERIMENTAL
Intervention: CT-Z (neoadjuvant chemotherapy + zoledronic acid)
Number of subjects: 188

Group type: COMPARATOR
Intervention: CT (neoadjuvant chemotherapy)
Number of subjects: 188
Study: 26165236

Group type: EXPERIMENTAL
Intervention: Supraglottic Airway Laryngopharyngeal Tube (S.A.L.T.)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 120
Study: 23248342

Group type: EXPERIMENTAL
Intervention: Teamwork Intervention (TI)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Asthma Education (AE)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 48
Study: 21979284

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18289334

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg thrice weekly (on Monday, Wednesday, and Saturday) for the first month, 250 mg thrice weekly for the second month, and 250 mg twice weekly for the third month.
Number of subjects: 67

Group type: COMPARATOR
Intervention: Doxycycline 100 mg/day for three months.
Number of subjects: 67
Study: 20687917

Group type: EXPERIMENTAL
Intervention: Standardised allergy training for healthcare professionals
Number of subjects: 230

Group type: COMPARATOR
Intervention: Usual care by healthcare professionals
Number of subjects: 230
Study: 15598198

Group type: EXPERIMENTAL
Intervention: TTM-based self-help manuals and sessions with an interactive computer program
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: TTM-based self-help manuals
Number of subjects: 393

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 393
Study: 12117042

Group type: EXPERIMENTAL
Intervention: Patient education with 4-hour schooling and individual consultations
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 9537607

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (15 mg orally twice a day for 5 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (isoenergetic diet without dexfenfluramine)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 8018756

Group type: EXPERIMENTAL
Intervention: Ensure HN (a complete, defined, pre-prepared low-fibre diet) for four days and two cleansing enemas the evening prior to the operation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Five days of residue-free hospital meals, cleansing enemas, laxatives, and three litres of polyethylene glycol solution
Number of subjects: 18
Study: 2688491

Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 790558

Group type: EXPERIMENTAL
Intervention: Terbutaline (0.25 mg subcutaneously)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 12
Study: 30668243

Group type: EXPERIMENTAL
Intervention: CRP plus 8.5% doxycycline hyclate gel
Number of subjects: 34

Group type: COMPARATOR
Intervention: CRP alone
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CRP plus 2% clindamycin hydrochloride gel
Number of subjects: 34
Study: 29776987

Group type: EXPERIMENTAL
Intervention: 150-μg subcutaneous glucagon (MDG)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 50% basal insulin reduction
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 40-g oral glucose tablets
Number of subjects: 15

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 15
Study: 26610183

Group type: EXPERIMENTAL
Intervention: Radial shock wave therapy (rESWT) with nightly splinting
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham rESWT with nightly splinting
Number of subjects: 34
Study: 25102684

Group type: EXPERIMENTAL
Intervention: Modified Taohongsiwu decoction (soaked for 30 min, once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pyridoxine (100 mg orally, twice daily)
Number of subjects: 0
Study: 21833673

Group type: EXPERIMENTAL
Intervention: Huperzine A (0.1‐mg bid)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (vitamin C 100‐mg bid)
Number of subjects: 78
Study: 19195847

Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injection (RLAI)
Number of subjects: 1622

Group type: COMPARATOR
Intervention: Oral antipsychotics (AP)
Number of subjects: 1622
Study: 17595037

Group type: EXPERIMENTAL
Intervention: Non-invasive pressure support ventilation (NI-PSV) with 7.9 ± 1.3 cm H2O above NCPAP pressure support
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP) at 5.3 ± 0.6 cm H2O
Number of subjects: 15
Study: 14727274

Group type: EXPERIMENTAL
Intervention: Midfemoral block (group MF)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Lateral sciatic nerve block (group PB)
Number of subjects: 63
Study: 11152919

Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate in one tablet daily (n = 768)
Number of subjects: 1525

Group type: COMPARATOR
Intervention: Placebo (n = 757)
Number of subjects: 1525
Study: 9589285

Group type: EXPERIMENTAL
Intervention: Behavioral Family Management (BFM) model
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Therapist competency and adherence ratings
Number of subjects: 26
Study: 7990242

Group type: EXPERIMENTAL
Intervention: High-intensity strength training exercises 2 days per week (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untreated controls (n = 19)
Number of subjects: 40
Study: 2657027

Group type: EXPERIMENTAL
Intervention: Nystatin pastille 200,000 units
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nystatin pastille 400,000 units
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24